The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signaling

Steffen Roßner, Uwe Ueberham, Reinhard Schliebs, J. Regino Perez-Polo, Volker Bigl

    Research output: Contribution to journalArticle

    178 Citations (Scopus)

    Abstract

    The increased expression and/or abnormal processing of the amyloid precursor protein (APP) is associated with the formation of amyloid plaques and cerebrovascular amyloid deposits, which are one of the major morphological hallmarks of Alzheimer's disease (AD). Among the processes regulating APP metabolism, the proteolytic cleavage of APP into amyloidogenic or nonamyloidogenic fragments is of special interest. The cleavage of the APP by the α-secretase within the β-amyloid sequence generates nonamyloidogenic C-terminal APP fragments and soluble APPsα, which has neurotrophic and neuroprotective activities. Proteolytic processing of APP by β-secretase, on the other hand, exposes the N-terminus of β-amyloid, which is liberated after γ-secretase cleavage at the variable amyloid C-terminus. The resulting 39-43 amino acid β-amyloid may be neurotoxic and disrupt neuronal connectivity after its accumulation in senile plaques. In this review, we discuss evidence derived from in vitro experiments, suggesting that the stimulation of protein kinase C (PKC)-coupled M1/M3 muscarinic acetylcholine receptors increases the nonamyloidogenic, secretory pathway of APP processing. It has also been shown in animal models that under conditions of reduced M1/M3 muscarinic acetylcholine receptor stimulation the secretory pathway of APP processing is inhibited and that constitutive upregulation of M1/M3-associated PKC increases APP secretion. Thus, the cortical cholinergic hypoactivity characteristic of AD may inhibit the nonamyloidogenic APP processing pathway and lead to increased β-amyloid generation. It has been shown in vitro that nerve growth factor (NGF)-associated signaling also influences the expression and catabolism of APP. Recent experiments with NGF- responsive cells revealed a specific role for the high-affinity NGF receptor, TrkA, in the increases in secretory APP processing and a role for the low- affinity neurotrophin receptor, p75(NTR), in the transcriptional regulation of APP. Therefore, treatments with NGF could ameliorate cortical cholinergic dysfunction in AD. These findings may influence the design of therapeutic strategies aimed at stimulating cholinergic function and at increasing nonamyloidogenic APP processing without elevating APP expression.

    Original languageEnglish (US)
    Pages (from-to)541-569
    Number of pages29
    JournalProgress in Neurobiology
    Volume56
    Issue number5
    DOIs
    StatePublished - Dec 1998

    Fingerprint

    Nerve Growth Factor Receptors
    Amyloid beta-Protein Precursor
    Cholinergic Receptors
    Amyloid
    Amyloid Precursor Protein Secretases
    Amyloid Plaques
    Nerve Growth Factor
    Cholinergic Agents
    Nerve Growth Factor Receptor
    Alzheimer Disease
    Secretory Pathway
    Muscarinic Receptors
    Protein Kinase C

    ASJC Scopus subject areas

    • Neuroscience(all)

    Cite this

    The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signaling. / Roßner, Steffen; Ueberham, Uwe; Schliebs, Reinhard; Regino Perez-Polo, J.; Bigl, Volker.

    In: Progress in Neurobiology, Vol. 56, No. 5, 12.1998, p. 541-569.

    Research output: Contribution to journalArticle

    Roßner, Steffen ; Ueberham, Uwe ; Schliebs, Reinhard ; Regino Perez-Polo, J. ; Bigl, Volker. / The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signaling. In: Progress in Neurobiology. 1998 ; Vol. 56, No. 5. pp. 541-569.
    @article{8805655a4a73447785db57decdf561bf,
    title = "The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signaling",
    abstract = "The increased expression and/or abnormal processing of the amyloid precursor protein (APP) is associated with the formation of amyloid plaques and cerebrovascular amyloid deposits, which are one of the major morphological hallmarks of Alzheimer's disease (AD). Among the processes regulating APP metabolism, the proteolytic cleavage of APP into amyloidogenic or nonamyloidogenic fragments is of special interest. The cleavage of the APP by the α-secretase within the β-amyloid sequence generates nonamyloidogenic C-terminal APP fragments and soluble APPsα, which has neurotrophic and neuroprotective activities. Proteolytic processing of APP by β-secretase, on the other hand, exposes the N-terminus of β-amyloid, which is liberated after γ-secretase cleavage at the variable amyloid C-terminus. The resulting 39-43 amino acid β-amyloid may be neurotoxic and disrupt neuronal connectivity after its accumulation in senile plaques. In this review, we discuss evidence derived from in vitro experiments, suggesting that the stimulation of protein kinase C (PKC)-coupled M1/M3 muscarinic acetylcholine receptors increases the nonamyloidogenic, secretory pathway of APP processing. It has also been shown in animal models that under conditions of reduced M1/M3 muscarinic acetylcholine receptor stimulation the secretory pathway of APP processing is inhibited and that constitutive upregulation of M1/M3-associated PKC increases APP secretion. Thus, the cortical cholinergic hypoactivity characteristic of AD may inhibit the nonamyloidogenic APP processing pathway and lead to increased β-amyloid generation. It has been shown in vitro that nerve growth factor (NGF)-associated signaling also influences the expression and catabolism of APP. Recent experiments with NGF- responsive cells revealed a specific role for the high-affinity NGF receptor, TrkA, in the increases in secretory APP processing and a role for the low- affinity neurotrophin receptor, p75(NTR), in the transcriptional regulation of APP. Therefore, treatments with NGF could ameliorate cortical cholinergic dysfunction in AD. These findings may influence the design of therapeutic strategies aimed at stimulating cholinergic function and at increasing nonamyloidogenic APP processing without elevating APP expression.",
    author = "Steffen Ro{\ss}ner and Uwe Ueberham and Reinhard Schliebs and {Regino Perez-Polo}, J. and Volker Bigl",
    year = "1998",
    month = "12",
    doi = "10.1016/S0301-0082(98)00044-6",
    language = "English (US)",
    volume = "56",
    pages = "541--569",
    journal = "Progress in Neurobiology",
    issn = "0301-0082",
    publisher = "Elsevier Limited",
    number = "5",

    }

    TY - JOUR

    T1 - The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signaling

    AU - Roßner, Steffen

    AU - Ueberham, Uwe

    AU - Schliebs, Reinhard

    AU - Regino Perez-Polo, J.

    AU - Bigl, Volker

    PY - 1998/12

    Y1 - 1998/12

    N2 - The increased expression and/or abnormal processing of the amyloid precursor protein (APP) is associated with the formation of amyloid plaques and cerebrovascular amyloid deposits, which are one of the major morphological hallmarks of Alzheimer's disease (AD). Among the processes regulating APP metabolism, the proteolytic cleavage of APP into amyloidogenic or nonamyloidogenic fragments is of special interest. The cleavage of the APP by the α-secretase within the β-amyloid sequence generates nonamyloidogenic C-terminal APP fragments and soluble APPsα, which has neurotrophic and neuroprotective activities. Proteolytic processing of APP by β-secretase, on the other hand, exposes the N-terminus of β-amyloid, which is liberated after γ-secretase cleavage at the variable amyloid C-terminus. The resulting 39-43 amino acid β-amyloid may be neurotoxic and disrupt neuronal connectivity after its accumulation in senile plaques. In this review, we discuss evidence derived from in vitro experiments, suggesting that the stimulation of protein kinase C (PKC)-coupled M1/M3 muscarinic acetylcholine receptors increases the nonamyloidogenic, secretory pathway of APP processing. It has also been shown in animal models that under conditions of reduced M1/M3 muscarinic acetylcholine receptor stimulation the secretory pathway of APP processing is inhibited and that constitutive upregulation of M1/M3-associated PKC increases APP secretion. Thus, the cortical cholinergic hypoactivity characteristic of AD may inhibit the nonamyloidogenic APP processing pathway and lead to increased β-amyloid generation. It has been shown in vitro that nerve growth factor (NGF)-associated signaling also influences the expression and catabolism of APP. Recent experiments with NGF- responsive cells revealed a specific role for the high-affinity NGF receptor, TrkA, in the increases in secretory APP processing and a role for the low- affinity neurotrophin receptor, p75(NTR), in the transcriptional regulation of APP. Therefore, treatments with NGF could ameliorate cortical cholinergic dysfunction in AD. These findings may influence the design of therapeutic strategies aimed at stimulating cholinergic function and at increasing nonamyloidogenic APP processing without elevating APP expression.

    AB - The increased expression and/or abnormal processing of the amyloid precursor protein (APP) is associated with the formation of amyloid plaques and cerebrovascular amyloid deposits, which are one of the major morphological hallmarks of Alzheimer's disease (AD). Among the processes regulating APP metabolism, the proteolytic cleavage of APP into amyloidogenic or nonamyloidogenic fragments is of special interest. The cleavage of the APP by the α-secretase within the β-amyloid sequence generates nonamyloidogenic C-terminal APP fragments and soluble APPsα, which has neurotrophic and neuroprotective activities. Proteolytic processing of APP by β-secretase, on the other hand, exposes the N-terminus of β-amyloid, which is liberated after γ-secretase cleavage at the variable amyloid C-terminus. The resulting 39-43 amino acid β-amyloid may be neurotoxic and disrupt neuronal connectivity after its accumulation in senile plaques. In this review, we discuss evidence derived from in vitro experiments, suggesting that the stimulation of protein kinase C (PKC)-coupled M1/M3 muscarinic acetylcholine receptors increases the nonamyloidogenic, secretory pathway of APP processing. It has also been shown in animal models that under conditions of reduced M1/M3 muscarinic acetylcholine receptor stimulation the secretory pathway of APP processing is inhibited and that constitutive upregulation of M1/M3-associated PKC increases APP secretion. Thus, the cortical cholinergic hypoactivity characteristic of AD may inhibit the nonamyloidogenic APP processing pathway and lead to increased β-amyloid generation. It has been shown in vitro that nerve growth factor (NGF)-associated signaling also influences the expression and catabolism of APP. Recent experiments with NGF- responsive cells revealed a specific role for the high-affinity NGF receptor, TrkA, in the increases in secretory APP processing and a role for the low- affinity neurotrophin receptor, p75(NTR), in the transcriptional regulation of APP. Therefore, treatments with NGF could ameliorate cortical cholinergic dysfunction in AD. These findings may influence the design of therapeutic strategies aimed at stimulating cholinergic function and at increasing nonamyloidogenic APP processing without elevating APP expression.

    UR - http://www.scopus.com/inward/record.url?scp=0001059974&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0001059974&partnerID=8YFLogxK

    U2 - 10.1016/S0301-0082(98)00044-6

    DO - 10.1016/S0301-0082(98)00044-6

    M3 - Article

    C2 - 9775403

    AN - SCOPUS:0001059974

    VL - 56

    SP - 541

    EP - 569

    JO - Progress in Neurobiology

    JF - Progress in Neurobiology

    SN - 0301-0082

    IS - 5

    ER -